• US therapeutic: $584M (+5% QoQ*, +9% YoY) • US cosmetic: $370M (-18% QoQ*, +4% YoY) -- US total: $954M (61% therapeutic; 39% cosmetic) was 71% of worldwide total
• Ex-US therapeutic: $115M (-5% QoQ*, +10% YoY†) • Ex-US cosmetic: $267M (+9% QoQ*, +55% YoY†) -- Ex-US total: $382M (30% therapeutic; 70% cosmetic) was 29% of worldwide total
*Botulinum-toxin sales are seasonally stronger during the second and fourth calendar quarters than the first and third calendar quarters.
†Ex-US growth measured in local currency.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”